keyword
MENU ▼
Read by QxMD icon Read
search

Prostate Cancer Screening Test

keyword
https://www.readbyqxmd.com/read/28428642/-technology-and-prevention-in-the-era-of-mobile-health-applications-for-cancer-screening-programs
#1
Fabrizio Bert, Maria Rosaria Gualano, Salvatore Clemente, Giulia Villa, Roberta Siliquini
The Italian national health system provides screening to detect breast, colorecatal and cervical cancers, however, population adherence is not as high as expected. Smartphones and their applications (apps) could be used as a tool to communicate with the population and to help improve adherence. The aim of this study was to analyze the features and functions of smartphone applications aimed at secondary prevention of oncological diseases. In February 2016, we reviewed online app stores, using specific key-words, to search for available apps for cancer screening...
January 2017: Igiene e Sanità Pubblica
https://www.readbyqxmd.com/read/28410183/online-versus-telephone-methods-to-recruit-and-interview-older-gay-and-bisexual-men-treated-for-prostate-cancer-findings-from-the-restore-study
#2
B R Simon Rosser, Benjamin Capistrant
BACKGROUND: Recently, researchers have faced the challenge of conflicting recommendations for online versus traditional methods to recruit and interview older, sexual minority men. Older populations represent the cohort least likely to be online, necessitating the use of traditional research methods, such as telephone or in-person interviews. By contrast, gay and bisexual men represent a population of early adopters of new technology, both in general and for medical research. In a study of older gay and bisexual men with prostate cancer, we asked whether respondents preferred online versus offline methods for data collection...
July 19, 2016: JMIR Cancer
https://www.readbyqxmd.com/read/28410180/rotterdam-prostate-cancer-risk-calculator-development-and-usability-testing-of-the-mobile-phone-app
#3
Nuno Pereira-Azevedo, Luís Osório, Avelino Fraga, Monique J Roobol
BACKGROUND: The use of prostate cancer screening tools that take into account relevant prebiopsy information (ie, risk calculators) is recommended as a way of determining the risk of cancer and the subsequent need for a prostate biopsy. This has the potential to limit prostate cancer overdiagnosis and subsequent overtreatment. mHealth apps are gaining traction in urological practice and are used by both practitioners and patients for a variety of purposes. OBJECTIVE: The impetus of the study was to design, develop, and assess a smartphone app for prostate cancer screening, based on the Rotterdam Prostate Cancer Risk Calculator (RPCRC)...
January 6, 2017: JMIR Cancer
https://www.readbyqxmd.com/read/28409907/the-roles-of-prostate-specific-antigen-psa-density-prostate-volume-and-their-zone-adjusted-derivatives-in-predicting-prostate-cancer-in-patients-with-psa-less-than-20-0%C3%A2-ng-ml
#4
P Shen, J Zhao, G Sun, N Chen, X Zhang, H Gui, Y Yang, J Liu, K Shu, Z Wang, H Zeng
The aim of this study was to develop nomograms for predicting prostate cancer and its zonal location using prostate-specific antigen density, prostate volume, and their zone-adjusted derivatives. A total of 928 consecutive patients with prostate-specific antigen (PSA) less than 20.0 ng/mL, who underwent transrectal ultrasound-guided transperineal 12-core prostate biopsy at West China Hospital between 2011 and 2014, were retrospectively enrolled. The patients were randomly split into training cohort (70%, n = 650) and validation cohort (30%, n = 278)...
May 2017: Andrology
https://www.readbyqxmd.com/read/28402085/decision-aids-for-people-facing-health-treatment-or-screening-decisions
#5
REVIEW
Dawn Stacey, France Légaré, Krystina Lewis, Michael J Barry, Carol L Bennett, Karen B Eden, Margaret Holmes-Rovner, Hilary Llewellyn-Thomas, Anne Lyddiatt, Richard Thomson, Lyndal Trevena
BACKGROUND: Decision aids are interventions that support patients by making their decisions explicit, providing information about options and associated benefits/harms, and helping clarify congruence between decisions and personal values. OBJECTIVES: To assess the effects of decision aids in people facing treatment or screening decisions. SEARCH METHODS: Updated search (2012 to April 2015) in CENTRAL; MEDLINE; Embase; PsycINFO; and grey literature; includes CINAHL to September 2008...
April 12, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28401443/prevalence-of-hypophysitis-in-a-cohort-of-patients-with-metastatic-melanoma-and-prostate-cancer-treated-with-ipilimumab
#6
Lucia Brilli, Riccardo Danielli, Cristina Ciuoli, Luana Calabrò, Anna Maria Di Giacomo, Alfonso Cerase, Patrizia Paffetti, Fausta Sestini, Brunetta Porcelli, Michele Maio, Furio Pacini
OBJECTIVE: Ipilimumab is a human monoclonal antibody directed against cytotoxic T-lymphocyte antigen-4, that has been shown to significantly improve survival in patients with metastatic melanoma. Blocking cytotoxic T-lymphocyte antigen-4 elicits T cell activation, proliferation and anti-tumor response, but can also trigger immune-related adverse events. Among immune-related endocrinopathies, hypophysitis represents the most frequent, with an incidence up to 17% in patients treated with ipilimumab...
April 12, 2017: Endocrine
https://www.readbyqxmd.com/read/28383613/can-psa-reflex-algorithm-be-a-valid-alternative-to-other-psa-based-prostate-cancer-screening-strategies
#7
G Caldarelli, G Troiano, D Rosadini, N Nante
BACKGROUND: The available laboratory tests for the differential diagnosis of prostate cancer, are represented by the total PSA, the free PSA, and the free/total PSA ratio. In Italy most of doctors tend to request both total and free PSA for their patients even in cases where the total PSA doesn't justify the further request of free PSA, with a consequent growth of the costs for the National Health System. The aim of our study was to predict the saving in Euro (due to reagents) and reduction in free PSA tests, applying the "PSA Reflex" algorithm...
May 2017: Annali di Igiene: Medicina Preventiva e di Comunità
https://www.readbyqxmd.com/read/28376460/persuasive-interventions-for-controversial-cancer-screening-recommendations-testing-a-novel-approach-to-help-patients-make-evidence-based-decisions
#8
Barry G Saver, Kathleen M Mazor, Roger Luckmann, Sarah L Cutrona, Marcela Hayes, Tatyana Gorodetsky, Nancy Esparza, Gonzalo Bacigalupe
PURPOSE: We wanted to evaluate novel decision aids designed to help patients trust and accept the controversial, evidence-based, US Preventive Services Task Force recommendations about prostate cancer screening (from 2012) and mammography screening for women aged 40 to 49 years (from 2009). METHODS: We created recorded vignettes of physician-patient discussions about prostate cancer screening and mammography, accompanied by illustrative slides, based on principles derived from preceding qualitative work and behavioral science literature...
January 2017: Annals of Family Medicine
https://www.readbyqxmd.com/read/28376164/germline-mutations-in-the-kallikrein-6-region-and-predisposition-for-aggressive-prostate-cancer
#9
Laurent Briollais, Hilmi Ozcelik, Jingxiong Xu, Maciej Kwiatkowski, Emilie Lalonde, Dorota H Sendorek, Neil E Fleshner, Franz Recker, Cynthia Kuk, Ekaterina Olkhov-Mitsel, Tristan Juvet, Ioannis Prassas, John Trachtenberg, Ants Toi, Michael Fraser, Theodorus van der Kwast, Robert G Bristow, Bharati Bapat, Eleftherios P Diamandis, Paul C Boutros, Alexandre R Zlotta
Background: There is a need for markers that can specifically identify individuals at increased risk of harboring aggressive forms of prostate cancer (PCa). Methods: We surveyed the Kallikrein ( KLK ) region ( KLK 1-15) for single-nucleotide polymorphisms (SNPs) associated with aggressive PCa (Gleason Score ≥ 8) in 1858 PCa patients. Discovery cohorts (Swiss arm of the European Randomized Study of Screening for PCa, n = 379; Toronto, Canada, n = 540) and a validation cohort (Prostate, Lung, Colorectal and Ovarian [PLCO] screening trial, n = 939) were analyzed...
April 1, 2017: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/28363265/two-stage-biomarker-protocols-for-improving-the-precision-of-early-detection-of-prostate-cancer
#10
Christine L Barnett, Scott A Tomlins, Daniel J Underwood, John T Wei, Todd M Morgan, James E Montie, Brian T Denton
BACKGROUND: New cancer biomarkers are being discovered at a rapid pace; however, these tests vary in their predictive performance characteristics, and it is unclear how best to use them. METHODS: We investigated 2-stage biomarker-based screening strategies in the context of prostate cancer using a partially observable Markov model to simulate patients' progression through prostate cancer states to mortality from prostate cancer or other causes. Patients were screened every 2 years from ages 55 to 69...
March 1, 2017: Medical Decision Making: An International Journal of the Society for Medical Decision Making
https://www.readbyqxmd.com/read/28351489/dying-for-love-perimenopausal-degeneration-of-vaginal-microbiome-drives-the-chronic-inflammation-malignant-transformation-of-benign-prostatic-hyperplasia-to-prostatic-adenocarcinoma
#11
Albert Stuart Reece
Prostatic carcinoma is the second commonest cancer in males and is so common as to become almost holoendemic with advancing age. The recent demonstration that far from being benign, "benign" prostatic hypertrophy is a likely a reaction of the prostate to chronic untreated lower genital tract infection, and that this chronic inflammation is likely the usual precursor to the frequent occurrence of prostatic carcinoma has far reaching implications. The obvious source for the chronic inflammatory stimulus in the prostate is the documented dramatically altered lower female genital microbiota associated with the menopause...
April 2017: Medical Hypotheses
https://www.readbyqxmd.com/read/28351193/measurement-of-serum-isoform-2-propsa-derivatives-shows-superior-accuracy-to-magnetic-resonance-imaging-in-the-diagnosis-of-prostate-cancer-in-patients-with-a-total-prostate-specific-antigen-level-of-2-10%C3%A2-ng-ml
#12
Kazuhiro Furuya, Takashi Kawahara, Masaki Narahara, Takashi Tokita, Sachi Fukui, Masashi Imano, Taku Mitome, Yusuke Ito, Koji Izumi, Kimito Osaka, Yumiko Yokomizo, Narihiko Hayashi, Hisashi Hasumi, Shintaro Nawata, Tsuyoshi Kawano, Masahiro Yao, Hiroji Uemura
OBJECTIVE: More accurate diagnostic procedures for prostate cancer are needed to avoid unnecessary biopsy due to the low specificity of prostate-specific antigen (PSA). Recent studies showed that the percentage of serum isoform [-2]proPSA (p2PSA) to free PSA (%p2PSA), the Prostate Health Index (PHI) and magnetic resonance imaging (MRI) were more accurate than PSA. The aim of this study was to test the accuracy of %p2PSA, PHI and MRI in discriminating patients with and without prostate cancer...
March 29, 2017: Scandinavian Journal of Urology
https://www.readbyqxmd.com/read/28347547/pace4-is-an-important-driver-of-zr-75-1-estrogen-receptor-positive-breast-cancer-proliferation-and-tumor-progression
#13
François Panet, Frédéric Couture, Anna Kwiatkowska, Roxane Desjardins, Brigitte Guérin, Robert Day
Breast cancer is the most frequent and deadly malignancy in women worldwide. Despite national screening programs combined with new treatments relapse rate remain high and new therapies are needed. From previous work, we identified PACE4, a member of the proprotein convertase (PCs) family of endoproteases, as a novel therapeutic target in prostate cancer. In the present study we asked the question if PACE4 could also be a potential target in breast cancer. In clinical samples of breast adenocarcinoma, we observed a specific overexpression of PACE4 in the estrogen-receptor (ER) positive subtype...
March 21, 2017: European Journal of Cell Biology
https://www.readbyqxmd.com/read/28345187/novel-biomarkers-for-prostate-cancer-an-evidence-based-review-for-use-in-clinical-practice
#14
REVIEW
Vikram M Narayan, Badrinath R Konety, Christopher Warlick
Prostate cancer is a heterogeneous disease with disparate outcomes. Traditional clinical parameters are limited in their ability to differentiate between these cases, and there is uncertainty regarding management strategies. A number of novel biomarkers have emerged, but how best to use them at the point of care remains confusing. In the present review, we describe the most common novel biomarkers, their key supporting literature, and propose a meaningful algorithm for their use in clinical practice. To identify commercially available prostate cancer diagnostic tests, we carried out a PubMed literature search (through May 2016)...
March 27, 2017: International Journal of Urology: Official Journal of the Japanese Urological Association
https://www.readbyqxmd.com/read/28343840/prostate-cancer-screening
#15
REVIEW
Mary Weinstein Dunn
OBJECTIVE: To review the current state of prostate cancer screening and future directions. DATA SOURCES: Nursing, medical and scientific literature related to prostate cancer screening, and national and international professional recommendations. CONCLUSION: Prostate cancer screening has been a topic of robust discussion for a number of years. Research continues to examine novel options for prostate cancer screening to either replace or compliment the prostate specific antigen test, but require additional validation before they will be widely accepted into clinical practice...
March 23, 2017: Seminars in Oncology Nursing
https://www.readbyqxmd.com/read/28343345/assessment-of-nucleosides-as-putative-tumor-biomarkers-in-prostate-cancer-screening-by-ce-uv
#16
Adriana Zardini Buzatto, Mariana de Oliveira Silva, Ronei Jesus Poppi, Ana Valéria Colnaghi Simionato
Cancer is responsible for millions of deaths worldwide, but most base diseases may be cured if detected early. Screening tests may be used to identify early-stage malignant neoplasms. However, the major screening tool for prostate cancer, the prostate-specific antigen test, has unsuitable sensitivity. Since cancer cells may affect the pattern of consumption and excretion of nucleosides, such biomolecules are putative biomarkers that can be used for diagnosis and treatment evaluation. Using a previously validated method for the analysis of nucleosides in blood serum by capillary electrophoresis with UV-vis spectroscopy detection, we investigated 60 samples from healthy individuals and 42 samples from prostate cancer patients...
March 25, 2017: Analytical and Bioanalytical Chemistry
https://www.readbyqxmd.com/read/28342633/pca3-as-a-second-line-biomarker-in-a-prospective-controlled-randomized-opportunistic-prostate-cancer-screening-programme
#17
J Rubio-Briones, J Casanova, F Martínez, J L Domínguez-Escrig, A Fernández-Serra, R Dumont, M Ramírez-Backhaus, A Gómez-Ferrer, A Collado, L Rubio, A Molina, M Vanaclocha, D Sala, J A Lopez-Guerrero
OBJECTIVES: PCA3 performance as a single second line biomarker is compared to the European Randomised Study of Screening for Prostate Cancer risk calculator model 3 (ERSPC RC-3) in an opportunistic screening in prostate cancer (PCa). MATERIAL AND METHODS: 5,199 men, aged 40-75y, underwent prostate-specific antigen (PSA) screening and digital rectal examination (DRE). Men with a normal DRE and PSA ≥3ng/ml had a PCA3 test done. All men with PCA3 ≥35 underwent an initial biopsy (IBx) -12 cores-...
March 22, 2017: Actas Urologicas Españolas
https://www.readbyqxmd.com/read/28338310/metastatic-prostate-cancer-in-the-modern-era-of-psa-screening
#18
Philip A Fontenot, Avinash Nehra, William Parker, Hadley Wyre, Moben Mirza, David A Duchene, Jeffrey Holzbeierlein, James Brantley Thrasher, Peter Van Veldhuizen, Eugene K Lee
INTRODUCTION: To characterize initial presentation and PSA screening status in a contemporary cohort of men treated for metastatic prostate cancer at our institution. MATERIALS AND METHODS: We reviewed records of 160 men treated for metastatic prostate cancer between 2008-2014 and assessed initial presentation, categorizing patients into four groups. Groups 1 and 2 presented with localized disease and received treatment. These men suffered biochemical recurrence late (>1 year) or earlier (<1 year), respectively, and developed metastases...
March 24, 2017: International Braz J Urol: Official Journal of the Brazilian Society of Urology
https://www.readbyqxmd.com/read/28327973/modeling-individual-and-relative-accuracy-of-screening-tools-in-geriatric-oncology
#19
C A Bellera, F Artaud, M Rainfray, P L Soubeyran, S Mathoulin-Pélissier
Background: Classification probabilities reflect to what degree a screening test represents the true disease state and include true positive (TPF) and false positive fractions (FPF). With two tests, one can compare TPF and FPF using relative probabilities which offer advantages in terms of interpretation and statistical modeling. Our objective was to highlight how individual and relative TPF and FPF can be easily estimated and compared within a regression modeling framework. This allows the modeling of tests' accuracy while adjusting for multiple covariates, and thus provides valuable information in addition to the crude TPF and FPF...
February 21, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28322897/the-state-of-pre-screening-discussions-about-psa-testing-following-implementation-of-the-2012-uspstf-task-force-statement
#20
George A Turini, Annie Gjelsvik, Joseph F Renzulli
OBJECTIVE: To determine if the quality of pre-screening discussions has changed following release of the USPSTF statement against prostate cancer screening. METHODS: This cross-sectional study utilized the 2012 and 2014 Behavioral Risk Factor Surveillance System (BRFSS) surveys. Respondents were categorized based on the year in which they responded to the BRFSS Survey. Quality of pre-screening discussion was operationalized as having discussed: only advantages, only disadvantages, both advantages and disadvantages, or neither...
March 16, 2017: Urology
keyword
keyword
89384
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"